ClinicalTrials.gg
RecruitingNCT07125729Updated Aug 12, 2026

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

An interventional study of Biospecimen Collection and cfDNA or ctDNA Measurement in Resectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8 and Stage III Colorectal Cancer AJCC v8, sponsored by City of Hope Medical Center. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Colorectal Neoplasms by City of Hope Medical Center — 17 open to participants now, 22 under way, 2 of them phase 3. Colorectal Neoplasms · City of Hope Medical Center.

Planned enrollment
4th of 28
150 · median 30
Started
2025
with 4 others
No phase
8 of 42
3 open now
Primary completion
2028-01
later than 6 of 21 live
Registered
32nd of 42
by date

Among the 42 studies in Colorectal Neoplasms by City of Hope Medical Center, this one is the 4th largest by planned enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2025, is one of 8 with no phase, reaches primary completion later than 6 of the 21 other live ones, and was the 32nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

17 of the 42 studies in Colorectal Neoplasms by City of Hope Medical Center are open now, in 5 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Colorectal Neoplasms by City of Hope Medical Center, or all of them as a file.
02

Study summary

This clinical trial compares minimal residual disease (MRD) testing with the Haystack blood test (assay) to the Signatera® assay for the early detection of the cancer returning (cancer recurrence) in patients with stage II-IV colorectal cancer (CRC) that can be removed by surgery (resectable). MRD testing looks for evidence of remaining tumor following treatment that is only apparent using highly sensitive techniques. There are few effective tools available outside of imaging to identify CRC patients with MRD who may be at the highest risk for cancer recurrence after surgery. Early detection of CRC recurrence after surgery is important, as it may increase the chance of curative (ability to cure) outcomes for patients with cancer recurrence. Currently, the Signatera assay is used to monitor whether CRC recurs after surgery, however it is not a very sensitive test. Early work with the Haystack assay suggests it may be more sensitive than the Signatera assay, which may be more effective for the early detection of cancer recurrence in patients with resectable stage II-IV CRC.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare the clinical performance of the Haystack MRD test and the Signatera® test in patients with stage II-IV CRC patients treated with curative intent surgery with or without adjuvant therapy.

SECONDARY OBJECTIVE:

I. To calculate the lead time (months) of recurrence detection by the Haystack MRD test in curatively resected colorectal cancer patients to 1) radiological recurrence time 2) Signatera® test positivity.

EXPLORATORY OBJECTIVE:

I. To explore the performance of up to two cancer detection assays (BestSEEK and enACT) in development by Dr. Tomasetti at City of Hope - Translational Genomics Research Institute (TGen) and City of Hope.

OUTLINE:

Patients undergo archival tissue and blood sample collection and Haystack MRD and Signatera circulating tumor deoxyribonucleic acid (ctDNA)/cell-free deoxyribonucleic acid (cfDNA) testing prior to standard of care (SOC) surgical resection. Patients then undergo blood sample collection and Haystack MRD and Signatera ctDNA/cfDNA testing 3-10 weeks after surgery, every 3 months for 2 years post-surgery, and then every 6 months for years 3-5 post-surgery in the absence of disease progression.

03

Conditions studied

  • Resectable Colorectal Carcinoma
  • Stage II Colorectal Cancer AJCC v8
  • Stage III Colorectal Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented written of the participant
  • Age: ≥ 18 years
  • Diagnosis of stage II, III or IV colorectal cancer (any gender) if enrolled post-operatively. If a treatment naïve patient is enrolled pre-operatively and determined to be pathological stage I, the patient will be replaced
  • Patient who are to undergo a curative intent surgery or have undergone a curative resection and are presenting for surveillance
  • Patient identified as an appropriate candidate for Signatera® testing as a standard of care MRD surveillance assay
  • Patient willingness to continue Signatera® assay every 3 months for 2 years in the first 2 years after resection and every 6 months for years 3, 4, 5 after resection, as performed by standard of care testing. In addition, the patients should be willing to provide blood samples for Haystack MRD testing at the same intervals of Signatera®, along with willingness to allow access to to allow for Haystack MRD assay personalization. Surveillance with ctDNA should be initiated between 3 to 10 weeks from surgery
  • Adequate availability of archival tissue or anticipated pathological viable tissue. All untreated primary resection would be expected to have adequate tissue. Patients with resected disease should have either previously resected primary that is amenable for tumor informed MRD testing or should have adequate archival metastasectomy samples
  • Patients with total therapy (TNT) for rectal cancer and complete clinical response with plans of watchful waiting may also be enrolled as long as there is adequate tissue from prior endoscopic biopsies to allow for Signatera® and Haystack MRD assays

Exclusion criteria

Exclusion Criteria:

  • Inability to safely provide sequential blood samples
  • Clinical evidence of unresected disease
  • Inability to give
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Screening (Haystack MRD, Signatera)

    Patients undergo archival tissue and blood sample collection and Haystack MRD and Signatera ctDNA/cfDNA testing prior SOC surgical resection. Patients then undergo blood sample collection and Haystack MRD and Signatera ctDNA/cfDNA testing 3-10 weeks after surgery, every 3 months for 2 years post-surgery, and then every 6 months for years 3-5 post-surgery in the absence of disease progression.

    Procedure: Biospecimen Collection · Other: cfDNA or ctDNA Measurement · Other: Electronic Health Record Review

Interventions

  • ProcedureBiospecimen Collection

    Undergo archival tissue and/or blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • OthercfDNA or ctDNA Measurement

    Undergo Haystack MRD and Signatera ctDNA/cfDNA testing

    Also known as: Cell-Free DNA/Circulating Tumor DNA Measurement, cfDNA/ctdDNA Measurement, cfDNA/ctDNA, cfDNA/ctDNA Measurement, Circulating Cell-Free DNA/Circulating Tumor-Derived DNA Measurement

  • OtherElectronic Health Record Review

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Minimal residual disease (MRD) rate with Haystack and Signatera®

    Will assess the MRD rate with Haystack (positive circulating tumor deoxyribonucleic acid \[+ctDNA\] and negative imaging) versus MRD rate with Signatera (+ctDNA and negative imaging). Sensitivity (i.e., true positive rate - proportion of patients who recur that are found to be MRD positive), specificity (i.e., true negative rate - proportion of patients who do NOT recur that are found to be MRD negative), positive predictive value (i.e., proportion of positive tests which are true positives) and negative predictive value (proportion of negative tests which are true negatives) of the Haystack test and of the Signatera test for predicting disease recurrence will be calculated and summarized at various times of testing.

    Time frame: Up to 5 years

Secondary outcomes

  1. Time interval of detection of disease recurrence by Haystack test, radiological imaging, and Signatera test

    The time interval between recurrence detection by the Haystack MRD test compared to radiological imaging assessment and Signatera test will be calculated as the time interval between the detection of disease recurrence by each of the methods (Haystack test, radiological imaging, Signatera test). Lead-time will be estimated by means of appropriate formulas and Monte Carlo simulation. Pairwise comparisons of detection times will be performed using the log-rank test. Cox proportional hazards model will be used to estimate the hazard ratios and 95% confidence intervals for each detection method.

    Time frame: Up to 5 years

  2. Level of association of circulating tumor deoxyribonucleic acid (ctDNA) result and status of recurrence and non-recurrence

    Logistic regression model will be used to estimate the level of association of ctDNA result and the status of recurrence and non- recurrence in patients with resectable stage II-IV colorectal cancer. Multivariable models adjusting for relevant clinical variables will be evaluated to assess the importance of these prognostic factors and support the robustness of ctDNA findings.

    Time frame: Up to 5 years

07

Study locations

13 of 13 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2028, 28 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 28 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2025
First posted
Aug 15, 2025
StartActual
Aug 29, 2025
Primary completionEst.
Jan 9, 2028
CompletionEst.
Jan 9, 2028
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07125729
Responsible party
Sponsor
First posted
Aug 15, 2025
Start date
Aug 29, 2025
Primary completion
Jan 9, 2028 (estimated)
Completion
Jan 9, 2028 (estimated)
Last update
Aug 12, 2026

Study contacts

Marwan G Fakih
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion